US-based medical device company QT Imaging Holdings Inc (OTCQB: QTIH) revealed on Monday that it has entered into an exclusive distribution agreement with Gulf Medical Co for the supply of its FDA-cleared Breast Acoustic CT scanner and subscriptions to the QTI Cloud Platform in Saudi Arabia.
The agreement sets minimum orders of five scanners per quarter beginning in the first quarter of 2026 through to the end of 2028, totalling at least 60 scanners and generating revenue of more than USD33m. Gulf Medical will also distribute QTI's AI-enabled cloud platform, designed to enhance breast health imaging through automated classification and second-read decision support.
QTI's non-invasive 3D breast imaging technology, which avoids compression, contrast agents and radiation, is particularly relevant in Saudi Arabia where genetic predispositions, including BRCA1 and BRCA2 mutations, contribute to higher breast cancer incidence among women aged 40 to 59.
Founded in 1983, Gulf Medical Co, part of the Al-Naghi Group, is a leading distributor of medical technologies across the Middle East.
QT Imaging Holdings is a US-based medical device company focused on safe, affordable and patient-centered imaging systems using low-frequency sound waves.
Novavax COVID-19 vaccine approved in US
Cantargia secures US patent for nadunolimab combination therapies
European Commission approves Bio-Thera Solutions' BAT2206
INOVIO to begin rolling submission of BLA for INO-3107
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Orsini named by Ionis as exclusive specialty pharmacy partner for DAWNZERA (donidalorsen)
Curasight's uTREAT clinical trial application approved in Europe
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Innovent Biologics receives approval over squamous cell lung cancer study
Crinetics Pharmaceuticals' atumelnant granted US FDA Orphan Drug Designation
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Hamlet BioPharma completes Phase II study of Alpha1H in non-muscle invasive bladder cancer